Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer
International Journal of Drug Research in Clinics · 15.03.2023 · 1 · e2
DOI: 10.34172/ijdrc.2023.e2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Research in Clinics, online erschienen am 15.03.2023. Verfasst von Sepideh Izadi und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Despite extensive attempts for the treatment of breast cancer (BC), it is the most prevalent cancer type among women, and its treatment remains elusive, particularly in patients with advanced disease. Although there are several therapeutic options, none of them is effective for complete relief, especially in metastatic patients. Cancer cells exhibit a high proliferation rate, which is usually associated with the dysregulation of cell cycle progress. Various proteins such as cyclin-dependent kinases (CDKs) and cyclins are involved in cell cycle modulation.
Methods
Databases including PubMed, Scopus, WebofScience and Google Scholar were used to extract information. Articles published in English until 2022 were used.
Results
Regarding the dysregulation of various CDKs in several cancer types, the pharmacologicalinhibitors of CDKs have extensively been evaluated to treat several cancer types such as BC. The blockade of CDKs strongly suppresses tumor growth through cell cycle arrest. Moreover, the combination of CDK inhibitors and other anti-cancer therapeutics has demonstrated potent synergistic effects on the treatment of various cancers.
Conclusion
Therefore, various CDK inhibitors have been designed and evaluated as antiproliferative therapeutics to suppress the proliferation of cancer cells. Pan CDK inhibitors, including flavopiridol, dinaciclib, purvalanol A, SNS-032, and roscovitine, are the most effective CDK inhibitors investigated in several studies. They inhibit various CDKs such as the CDK1, 2, 4, 5, 6, 7, and 9. In this review, it is attempted to discuss the efficacy of Pan CDK inhibitors as an anti-cancer therapy in BC.
Zitieren
APA
Izadi, S., Farsang, M. H., Karpisheh, V., & Jadidi-Niaragh, F. (2023). Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer. International Journal of Drug Research in Clinics, 1, e2. https://doi.org/10.34172/ijdrc.2023.e2
Vancouver
Izadi S, Farsang MH, Karpisheh V, Jadidi-Niaragh F. Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer. International Journal of Drug Research in Clinics. 2023;1:e2. doi:10.34172/ijdrc.2023.e2
BibTeX
@article{Izadi2023,
author = {Izadi, Sepideh and Farsang, Mohammad Hojjat and Karpisheh, Vahid and Jadidi-Niaragh, Farhad},
title = {Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer},
journal = {International Journal of Drug Research in Clinics},
year = {2023},
volume = {1},
pages = {e2},
doi = {10.34172/ijdrc.2023.e2}
}
EUVIMED